Overview

A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Status:
Completed

Trial end date:
2017-05-25

Target enrollment:

Participant gender:

Summary

The purpose of this study is to monitor the safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Europe B.V.

Collaborator:

Medivation, Inc.

Treatments:

Docetaxel